Gout: Evaluation and Management
Gout Disease


DOI:
https://doi.org/10.5281/zenodo.16740509Keywords:
Hyperuricemia, Gout, Urate Oxidase/metabolism, ArthritisAbstract
Uric acid is a byproduct of purine nucleotide metabolism, primarily synthesized in the liver and less frequently in other tissues. Hyperuricemia, characterized by elevated uric acid levels, can lead to gout and nephrolithiasis. It is also associated with conditions such as hypertension, metabolic syndrome, cardiovascular disease, and chronic kidney disease. Gout is an inflammatory disease marked by the deposition of monosodium urate (MSU) crystals in joints and tissues. It commonly affects the metatarsophalangeal joint, followed by other lower extremity joints, making it the most prevalent inflammatory arthritis. The pathophysiology of gout involves pro-inflammatory cytokines, lipid mediators, and the complement system, which contribute to the initiation and exacerbation of gout flares. Diagnosis relies on clinical evaluation, the identification of MSU crystals, and radiological imaging. Treatment encompasses acute gout flare management, prophylaxis, dietary modifications, and urate-lowering therapies. Common therapeutic agents include nonsteroidal anti-inflammatory drugs, colchicine, glucocorticoids, adrenocorticotropic hormone, and anti-IL-1β biological agents.
References
George C, Leslie SW, Minter DA. Hyperuricemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan‑. Updated Oct 14, 2023. Accessed Aug 3, 2025. https://www.ncbi.nlm.nih.gov/books/NBK459218/
Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: A clinical review. J Cardiol. 2021;78(1):51-57. doi:10.1016/j.jjcc.2020.12.013
Huzmeli C, Öztürk K, Güllü M, Canım Y, Uçar E, Candan F. The probable cause of hypouricemia; Xanthinuria. Med J Mustafa Kemal Univ. 2019;10(36):25–26. doi:10.17944/mkutfd.494816.
Park JH, Jo YI, Lee JH. Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med. 2020;35(6):1291-1304. doi:10.3904/kjim.2020.410
Kannuthurai V, Gaffo A. Management of Patients with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps. Kidney360. 2023;4(9):e1332-e1340. doi:10.34067/KID.0000000000000221
Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther. 2006;8 Suppl 1(Suppl 1):S1. doi:10.1186/ar1906
Bhattacharjee S. A brief history of gout. Int J Rheum Dis. 2009;12(1):61-63. doi:10.1111/j.1756-185X.2009.01381.x
Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. 2012;63(4):199-206. Published 2012 Jan 19. doi:10.4081/reumatismo.2011.199
Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum. 2021;51(1):121-128. doi:10.1016/j.semarthrit.2020.12.001
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390. doi:10.1038/s41584-020-0441-1
Song J, Jin C, Shan Z, Teng W, Li J. Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China. J Transl Int Med. 2022;10(2):134-145. Published 2022 Jul 7. doi:10.2478/jtim-2022-0031
Dehlin M, Drivelegka P, Sigurdardottir V, Svärd A, Jacobsson LT. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016;18:164. Published 2016 Jul 13. doi:10.1186/s13075-016-1062-6
Yokose C, McCormick N, Lu N, et al. Trends in Prevalence of Gout Among US Asian Adults, 2011-2018. JAMA Netw Open. 2023;6(4):e239501. Published 2023 Apr 3. doi:10.1001/jamanetworkopen.2023.9501
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991-999. doi:10.1002/art.40807
Quilis N, Sivera F, Seoane-Mato D, et al. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases. Joint Bone Spine. 2022;89(1):105257. doi:10.1016/j.jbspin.2021.105257
McCormick N, Lu N, Yokose C, et al. Racial and Sex Disparities in Gout Prevalence Among US Adults. JAMA Netw Open. 2022;5(8):e2226804. Published 2022 Aug 1. doi:10.1001/jamanetworkopen.2022.26804
Safiri S, Kolahi AA, Cross M, et al. Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Arthritis Rheumatol. 2020;72(11):1916-1927. doi:10.1002/art.41404
Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):S11-S16. doi:10.1016/j.semarthrit.2020.04.008
Abhishek A, Valdes AM, Jenkins W, Zhang W, Doherty M. Triggers of acute attacks of gout, does age of gout onset matter? A primary care based cross-sectional study. PLoS One. 2017;12(10):e0186096. Published 2017 Oct 12. doi:10.1371/journal.pone.0186096
Helget LN, Mikuls TR. Environmental Triggers of Hyperuricemia and Gout. Rheum Dis Clin North Am. 2022;48(4):891-906. doi:10.1016/j.rdc.2022.06.009
Nian YL, You CG. Susceptibility genes of hyperuricemia and gout. Hereditas. 2022;159(1):30. Published 2022 Aug 4. doi:10.1186/s41065-022-00243-y
Grassi W, De Angelis R. Clinical features of gout. Reumatismo. 2012;63(4):238-245. Published 2012 Jan 19. doi:10.4081/reumatismo.2011.238
Saad M. Hyperuricemia and Gout: The Role of Losartan. Sr Care Pharm. 2023;38(9):359-360. doi:10.4140/TCP.n.2023.359
Herman LL, Weber P, Bashir K. Hydrochlorothiazide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated Nov 12, 2023. Accessed Aug 4, 2025.
Narang RK, Dalbeth N. Pathophysiology of Gout. Semin Nephrol. 2020;40(6):550-563. doi:10.1016/j.semnephrol.2020.12.001
Murdoch R, Barry MJ, Choi HK, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. RMD Open. 2021;7(2):e001623. doi:10.1136/rmdopen-2021-001623
Weaver JS, Vina ER, Munk PL, Klauser AS, Elifritz JM, Taljanovic MS. Gouty Arthropathy: Review of Clinical Manifestations and Treatment, with Emphasis on Imaging. J Clin Med. 2021;11(1):166. Published 2021 Dec 29. doi:10.3390/jcm11010166
Tao H, Mo Y, Liu W, Wang H. A review on gout: Looking back and looking ahead. Int Immunopharmacol. 2023;117:109977. doi:10.1016/j.intimp.2023.109977
Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae DS. Pathophysiology and Treatment of Gout Arthritis; including Gout Arthritis of Hip Joint: A Literature Review. Hip Pelvis. 2024;36(1):1-11. doi:10.5371/hp.2024.36.1.1
Duan L, Zhong J, Yang Y, Zhu X. Editorial: Advances in Pathogenesis and Therapies of Gout. Front Immunol. 2022;13:890204. Published 2022 Apr 1. doi:10.3389/fimmu.2022.890204
Schumacher HR Jr. The pathogenesis of gout. Cleve Clin J Med. 2008;75 Suppl 5:S2-S4. doi:10.3949/ccjm.75.suppl_5.s2
Desai J, Steiger S, Anders HJ. Molecular Pathophysiology of Gout. Trends Mol Med. 2017;23(8):756-768. doi:10.1016/j.molmed.2017.06.005
Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75 Suppl 5:S5-S8. doi:10.3949/ccjm.75.suppl_5.s5
Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system?. Ann Rheum Dis. 2014;73(9):1598-1600. doi:10.1136/annrheumdis-2014-205304
Koto R, Nakajima A, Horiuchi H, Yamanaka H. Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data. Mod Rheumatol. 2021;31(1):261-269. doi:10.1080/14397595.2020.1784556
Duffy M, Hughes S. Gout: clinical features and diagnosis. Clin. Pharm. 2012;4(3):73‑76.
Afzal M, Rednam M, Gujarathi R, Widrich J. Gout. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. Updated Jun 23, 2025. Accessed Aug 4, 2025. PMID: 31536213.
Diaz-Torne C, Ortiz MA, Garcia-Guillen A, et al. The inflammatory role of silent urate crystal deposition in intercritical gout. Rheumatology (Oxford). 2021;60(11):5463-5472. doi:10.1093/rheumatology/keab335
Espejo D, Dearing E, Ogle KY, Portela M, Boniface KS. Images in Primary Care Medicine: Point-of-Care Ultrasound in Gout. Cureus. 2021;13(5):e15096. Published 2021 May 18. doi:10.7759/cureus.15096
Sivera F, Andrès M, Falzon L, van der Heijde DM, Carmona L. Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. J Rheumatol Suppl. 2014;92:3-8. doi:10.3899/jrheum.140456
Zha X, Yang B, Xia G, Wang S. Combination of Uric Acid and Pro-Inflammatory Cytokines in Discriminating Patients with Gout from Healthy Controls. J Inflamm Res. 2022;15:1413-1420. Published 2022 Feb 28. doi:10.2147/JIR.S357159
Baffour FI, Ferrero A, Aird GA, et al. Evolving Role of Dual-Energy CT in the Clinical Workup of Gout: A Retrospective Study. AJR Am J Roentgenol. 2022;218(6):1041-1050. doi:10.2214/AJR.21.27139
Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79(1):31-38. doi:10.1136/annrheumdis-2019-215315
Neilson J, Bonnon A, Dickson A, Roddy E; Guideline Committee. Gout: diagnosis and management-summary of NICE guidance. BMJ. 2022;378:o1754. Published 2022 Aug 30. doi:10.1136/bmj.o1754
Khanna P, Johnson RJ, Marder B, LaMoreaux B, Kumar A. Systemic Urate Deposition: An Unrecognized Complication of Gout?. J Clin Med. 2020;9(10):3204. Published 2020 Oct 3. doi:10.3390/jcm9103204
Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med. 2012;125(7):679-687.e1. doi:10.1016/j.amjmed.2011.09.033
Gibson TJ. Hypertension, its treatment, hyperuricaemia and gout. Curr Opin Rheumatol. 2013;25(2):217-222. doi:10.1097/BOR.0b013e32835cedd4
Cox P, Gupta S, Zhao SS, Hughes DM. The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis. Rheumatol Int. 2021;41(7):1209-1219. doi:10.1007/s00296-021-04876-6
Asghari KM, Zahmatyar M, Seyedi F, et al. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord. 2024;25(1):1047. Published 2024 Dec 19. doi:10.1186/s12891-024-08180-9
KC M, Leslie SW. Uric Acid Nephrolithiasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 15, 2023.
Hoff LS, Goldenstein-Schainberg C, Fuller R. Nephrolithiasis in gout: prevalence and characteristics of Brazilian patients. Adv Rheumatol. 2019;60(1):2. Published 2019 Dec 31. doi:10.1186/s42358-019-0106-4
Rakhmatov AM, Jabbarov AA, Kodirova SA, Jumanazarov SB. Clinical manifestations of gouty nephropathy. *Theoretical Aspects in the Formation of Pedagogical Sciences*. 2022;1(6):140‑141. doi:10.5281/zenodo.7322196
Lusco MA, Fogo AB, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Gouty Nephropathy. Am J Kidney Dis. 2017;69(1):e5-e6. doi:10.1053/j.ajkd.2016.11.006
Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7(11):e50046. doi:10.1371/journal.pone.0050046
Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. Published 2015 Apr 1. doi:10.1186/s13075-015-0610-9
Bardin T, Letavernier E, Correas J M. The gouty kidney: A reappraisal. Gout Urate Cryst Depos Dis. 2023;1(1):25 36. doi:10.3390/gucdd1010004.
Jiang Y, Brenner JE, Foster WJ. Retinal complications of gout: a case report and review of the literature. BMC Ophthalmol. 2018;18(1):11. Published 2018 Jan 19. doi:10.1186/s12886-018-0669-6
Ma S, Zhao J, Jiang R, An Q, Gu R. Diagnostic challenges of spinal gout: A case series. Medicine (Baltimore). 2019;98(16):e15265. doi:10.1097/MD.0000000000015265
Towiwat P, Chhana A, Dalbeth N. The anatomical pathology of gout: a systematic literature review. BMC Musculoskelet Disord. 2019;20(1):140. Published 2019 Apr 1. doi:10.1186/s12891-019-2519-y
Kakutani-Hatayama M, Kadoya M, Okazaki H, et al. Nonpharmacological Management of Gout and Hyperuricemia: Hints for Better Lifestyle. Am J Lifestyle Med. 2015;11(4):321-329. Published 2015 Sep 2. doi:10.1177/1559827615601973
Abhishek A, Doherty M. Education and non-pharmacological approaches for gout. Rheumatology (Oxford). 2018;57(suppl_1):i51-i58. doi:10.1093/rheumatology/kex421
Uhlig T, Karoliussen LF, Sexton J, et al. Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. Rheumatology (Oxford). 2025;64(4):1799-1806. doi:10.1093/rheumatology/keae514
Brzezińska O, Styrzyński F, Makowska J, Walczak K. Role of Vitamin C in Prophylaxis and Treatment of Gout-A Literature Review. Nutrients. 2021;13(2):701. Published 2021 Feb 22. doi:10.3390/nu13020701
Deeks ED. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017;34(5):401-410. doi:10.1007/s40266-017-0461-y
Schlesinger N, Lipsky PE. Pegloticase treatment of chronic refractory gout: Update on efficacy and safety. Semin Arthritis Rheum. 2020;50(3S):S31-S38. doi:10.1016/j.semarthrit.2020.04.011
Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and Diet: A Comprehensive Review of Mechanisms and Management. Nutrients. 2022;14(17):3525. Published 2022 Aug 26. doi:10.3390/nu14173525
Chiu THT, Liu CH, Chang CC, Lin MN, Lin CL. Vegetarian diet and risk of gout in two separate prospective cohort studies. Clin Nutr. 2020;39(3):837-844. doi:10.1016/j.clnu.2019.03.016
El-Reshaid K, Al-Bader S, Sallam H. "Recurrent Papillary Necrosis and Nephrocalcinosis Induced by Nonsteroidal Anti-Inflammatory Drugs for Gouty Arthritis Associated with Congenital Chloride-Losing Diarrhea: A Major Risk for Kidney Loss". Case Rep Nephrol. 2021;2021:3558278. Published 2021 Oct 16. doi:10.1155/2021/3558278
Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3S):S24-S30. doi:10.1016/j.semarthrit.2020.04.010
Kaul S, Gupta M, Bandyopadhyay D, et al. Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. Am J Cardiovasc Drugs. 2021;21(5):499-512. doi:10.1007/s40256-020-00459-1
Solak Y, Siriopol D, Yildiz A, et al. Colchicine in Renal Medicine: New Virtues of an Ancient Friend. Blood Purif. 2017;43(1-3):125-135. doi:10.1159/000454669
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879-895. doi:10.1002/art.41247
Klück V, Liu R, Joosten LAB. The role of interleukin-1 family members in hyperuricemia and gout. Joint Bone Spine. 2021;88(2):105092. doi:10.1016/j.jbspin.2020.105092
Stamp LK, Farquhar H, Pisaniello HL, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633-641. doi:10.1038/s41584-021-00657-4
Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021;30(2):122-130. doi:10.1159/000512178
Wei J, Choi HK, Dalbeth N, et al. Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes. JAMA Netw Open. 2023;6(8):e2330885. Published 2023 Aug 1. doi:10.1001/jamanetworkopen.2023.30885
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Can Hüzmeli

This work is licensed under a Creative Commons Attribution 4.0 International License.